178 related articles for article (PubMed ID: 26144698)
21. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
22. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
23. Exercise-induced radio-iodine accumulation in scalp and hair during admission of 131I therapy for thyroid cancer.
Zakavi SR; Kakhki VD
Thyroid; 2006 Nov; 16(11):1185-6. PubMed ID: 17123349
[No Abstract] [Full Text] [Related]
24. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
25. Post-therapy iodine-131 localization in unsuspected large renal cyst: possible mechanisms.
Wen C; Iuanow E; Oates E; Lee SL; Perrone R
J Nucl Med; 1998 Dec; 39(12):2158-61. PubMed ID: 9867161
[TBL] [Abstract][Full Text] [Related]
26. Unusual intratracheal metastasis of differentiated thyroid cancer accurately depicted by SPECT/CT acquisition after radioiodine ablation.
Aide N; Lehembre E; Gervais R; Bardet S
Thyroid; 2007 Dec; 17(12):1305-6. PubMed ID: 17949266
[No Abstract] [Full Text] [Related]
27. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
28. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.
Handkiewicz-Junak D; Wloch J; Roskosz J; Krajewska J; Kropinska A; Pomorski L; Kukulska A; Prokurat A; Wygoda Z; Jarzab B
J Nucl Med; 2007 Jun; 48(6):879-88. PubMed ID: 17536106
[TBL] [Abstract][Full Text] [Related]
29. [Pathological thyroid uptake in Cushing's syndrome: an unexpected finding].
Civantos Modino S; Montaño Martínez J; Pavón de Paz I; Guijarro de Armas G; Monereo Megías S
Endocrinol Nutr; 2011; 58(6):315-7. PubMed ID: 21497569
[No Abstract] [Full Text] [Related]
30. 99mTc-MIBI in differentiated thyroid carcinoma.
Roelants V; Beckers C
J Nucl Med; 1999 Oct; 40(10):1769. PubMed ID: 10520721
[No Abstract] [Full Text] [Related]
31. SPECT/CT identification of post-radioactive iodine treatment false-positive uptake in a simple renal cyst.
Thust S; Fernando R; Barwick T; Mohan H; Clarke SE
Thyroid; 2009 Jan; 19(1):75-6. PubMed ID: 19119982
[No Abstract] [Full Text] [Related]
32. Metastatic thyroid cancer visualized on technetium pertechnetate and iodine-131 scintigraphy.
Verma N; Singh-Wadhwa S; Arvela OM
Clin Nucl Med; 2002 Aug; 27(8):610. PubMed ID: 12170017
[No Abstract] [Full Text] [Related]
33. Mediastinal images resembling thymus following 131-I treatment for thyroid cancer.
Montella L; Caraglia M; Abbruzzese A; Soricelli A; Caputi M; Squame G; Salvatore M; Del Prete S; Palmieri G
Monaldi Arch Chest Dis; 2005 Jun; 63(2):114-7. PubMed ID: 16128228
[TBL] [Abstract][Full Text] [Related]
34. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
35. [Thymic uptake of 18FFDG following radioiodine ablation therapy].
Albalá González MD; Martínez Gimeno E; Cárdenas Negro C; Allende Riera A; Cabello García D; De Sequera Rahola M; Uña Gorospe JA
Rev Esp Med Nucl; 2011; 30(5):314-6. PubMed ID: 21342725
[TBL] [Abstract][Full Text] [Related]
36. [Metastatic adenopathy from a thyroid microcarcinoma: final diagnosis of a presumed paraganglioma].
Varsavsky M; Cortés Berdonces M; Alonso G; García Martín A; Muñoz Torres M
Endocrinol Nutr; 2011 Mar; 58(3):143-4. PubMed ID: 21339089
[No Abstract] [Full Text] [Related]
37. Incidental thyroid 99mTc-MDP uptake in a patient affected by differentiated thyroid cancer.
Albano D; Magri GC; Treglia G; Bertagna F
Nucl Med Rev Cent East Eur; 2016; 19(B):8-10. PubMed ID: 27813621
[TBL] [Abstract][Full Text] [Related]
38. Contemporary management of papillary carcinoma of the thyroid gland.
Rosenbaum MA; McHenry CR
Expert Rev Anticancer Ther; 2009 Mar; 9(3):317-29. PubMed ID: 19275510
[TBL] [Abstract][Full Text] [Related]
39. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
Yap BK; Murby B
J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
[TBL] [Abstract][Full Text] [Related]
40. Orbital metastasis as primary manifestation of thyroid carcinoma.
Daumerie C; De Potter P; Godfraind C; Rahier J; Jamar F; Squifflet JP
Thyroid; 2000 Feb; 10(2):189-92. PubMed ID: 10718558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
